AHI and Discovery take next step with real-time data trial

|

Published 05-MAY-2021 10:42 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Advanced Human Imaging Ltd (ASX:AHI) has provided a positive update regarding the consumer pilot to be conducted with Discovery Vitality, a subsidiary of Discovery Limited, a leading insurance and financial services provider.

AHI and Vitality have been working together over the last 12 months testing the AHI technology.

After a number of successful outcomes, Vitality has decided to conduct a larger consumer-facing pilot facilitated by onsite wellness specialists at four Discovery facilities in South Africa.

The intention of the pilot is to demonstrate the real-time data accuracy and efficiencies of the CompleteScan system.

The pilot will run throughout the month of May with wellness specialists performing an onsite health evaluation of each participant, comparing the accuracy of the results to those when utilising the CompleteScan application capture suite.

AHI and Discovery are in commercial discussions for ongoing access to the application.

This is an important development for the group as it reinforces the breadth of commercial opportunities where the CompleteScan application can be employed.

Highlights CompleteScan’s breadth of applications

The technology is more than just health-focused - it can provide valuable data for employers outside the health industry, as well as being a useful source of information for insurers.

AHI referred to Discovery as the pioneers of rewards-based incentivised health outcomes, highlighting that the CompleteScan integration will deliver a high-quality cost-effective data set that will have exponential value in risk assessment and management when integrated into a solution like Vitality.

Summing up what represents a win-win situation, AHI chief executive Vlado Bosanac said, "Better health outcomes mean better quality of life.

"The ethos of a platform of this nature is to do exactly that - help people live better healthier lives.

"This is where the CompleteScan application is most effective, by identifying negative health indicators through actionable data for early intervention.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X